Skip to main content
OpenTrials
Completed

NCT Number: NCT03661060

BLITZ Heart Failure

To evaluate if Italian Cardiologists are treating Heart Failure (HF) patients according to International guidelines and if a structured educational program can improved their adherence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedali Riuniti - Sod Cardiologia Ospedaliera Emod. E Utic, Ancona, AN, Italy

Loading trial locations.

About this study

Multicentre, cross-sectional, prospective, non-interventional, observational study designed to evaluate the level of adherence to current ESC guidelines recommendations in both acute and chronic HF patients enrolled in each participating center and to verify if a specific HF educational intervention composed by an educational web based program of data collection and face to face meetings is able to improve adherence to guidelines recommendations evaluated during a second enrollment period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All consecutive patients with chronic HF and those admitted for acute (de novo) or worsening chronic HF.
  • Chronic HF: any NYHA class (I-IV).
  • Acute HF Only patients in NYHA class III or IV, or with pulmonary edema or cardiogenic shock for whom an IV therapy specific for HF (diuretic, vasodilators, vasopressors) is administered.
  • Any gender.
  • Any etiology of HF.
  • Any level of EF.
  • Written informed consent.

Exclusion criteria

  • - Age <18 years.
  • Inclusion in registries or trials that can influence, by protocol, the clinical management of patients.
  • Patients already enrolled in the BLITZ HF (by another participating centre or in the first enrollment period).

Treatment and study plan

Primary outcomes

  1. Adherence to current guideline

    Time frame: Enrollment

    To assess number of patients managed and treated following the 2016 ESC Heart Failure Gudelines (acute HF, chronic HFrEF, chronic HFmrEF, chronic HFpEF).

  2. Patients managed and treated following International Guideline

    Time frame: 24 months

    Patients treatment in phase 1 versus phase 3

Secondary outcomes

  1. Mortality

    Time frame: 12 months Follow-up

    Death from all-causes, for cardiovascular causes, for HF

  2. Morbidity

    Time frame: 12 months Follow-up

    Hospital admissions from all-causes, for cardiovascular causes, for HF

  3. Indication to heart failure device implantation

    Time frame: Enrollement

    The rate of patients with chronic HFrEF with an indication to ICD and/or CRT planned in clinical practice

  4. Prescription rate of disease modifying drugs

    Time frame: Enrollment

    The rate of patients with HFrEF receiving all the drugs recommended by current guidelines: ACE-Is/ARBs, betablockers and MRAs, in the absence of specific contraindications/intolerance.

  5. Oral anticoagulation prescription in patients with AF

    Time frame: Enrollment

    Rate of patients treated with oral anticoagulants in case of AF

  6. Use of ARNI

    Time frame: Enrollment

    The rate of implementation of a new drug approach (ARNI) for patients with HF and EF ≤35%

  7. Creatinine and EF evaluation

    Time frame: Enrollment

    The rate of CHF patients with an available measure of EF and of creatinine.

Sponsors and collaborators

Lead sponsor

Heart Care Foundation

Other

Registry information

Acronym: BLITZ-HF

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Sep 7, 2018
Registry last updated
Jul 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.